S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)

The purpose of this study is to find out what effects, good and/or bad, the combination of regular chemotherapy plus pravastatin has on Relapsed Acute Myelogenous Leukemia (AML) patients. The chemotherapy is made up of two drugs which are commonly used to treat your type of leukemia. These drugs are Idarubicin and ARA-C (Cytarabine). Pravastatin is a drug that is usually used to treat high cholesterol. We would like to see whether adding Pravastatin to the chemotherapy will have an effect. Since Pravastatin is not usually used to treat leukemia, it will be considered investigational for this study.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : cytarabine
  • drug : pravastatin sodium
  • drug : idarubicin

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

External Links

Explore related trials

Contact information

Primary Contact:

Joselene Sipin-Sayno 650-736-8113

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: